MTOR and cancer: Furthermore, it could be speculated that KD can increase the effect of pharmacological treatment, acting on IL-6, VEGF, and PI3K/AKT/mTOR pathways [100]; this strengthens the idea that KD could be considered an “adjuvant cancer therapy”, translatable in the management of NETs.